SMAD3 and leiomyoma: Additionally, gonadotropin‐releasing hormone analog (GnRHa) therapy decreases TGF‐βRs, SMAD3 and SMAD4 along with an increase in SMAD7 expression in both myometrium and leiomyoma tissues compared to untreated control.42